Neoadjuvant and adjuvant treatment modalities for prostate cancer

Prostate cancer is the most common cancer among men and the 2nd that cause oncological deaths. Today, as PSA has been adjusted to daily urology practice as a screening, tool; it gives the opportunity to diagnose increasing number of prostate cancer, even in earlier stages. As more cases fall into group of curable disease by years, treatment modalities and technique has developed and begun to be used in combination. Radiotherapy following surgery has already been an option for a long time. Chemotherapeutics will also take more place in combinations besides the contribution of androgen deprivation treatment to radiotherapy and surgery in prostate cancer that's hormone dependent. However, there is still no consensus about optimization, timing and duration of these combinations as well as patient selection. In this review, adjuvant and neoadjuvant treatment options are discussed in search for the ideal in prostate cancer.